Contemporary use of bevacizumab in ovarian cancer

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
   PubMed Web of Science ®Google Scholar
• Bristow RE, Tomacruz RS, Armstrong DK, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;120(5):1248-59
   PubMed Web of Science ®Google Scholar
• Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009;19(Suppl 2):S63-7
   PubMedGoogle Scholar
• Ziebarth AJ, Landen CN Jr, Alvarez RD. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol 2012;55(1):156-72
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17(11):1359-70
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40
   PubMedGoogle Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;19473(7347):298-307
   PubMed Web of Science ®Google Scholar
• Angiogenesis inhibitors. National Cancer Institute at the National Institutes of health. Bethesda, MD. Available from: http://www.cancer.gov/cancertopics/factsheet/Therapy/angiogenesis-inhibitors
   Google Scholar
• Matei D, Sill MW, Lankes HA, Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011;129(1):69-75
   PubMed Web of Science ®Google Scholar
• Biagi JJ, Oza AM, Chalchal HI, A Phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011;22(2):335-40
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Berlin S, Ivy P, Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;2027(33):5601-6
   PubMed Web of Science ®Google Scholar
• Friedlander M, Hancock KC, Rischin D, A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32-7
   PubMed Web of Science ®Google Scholar
• Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175(3):409-16
   PubMed Web of Science ®Google Scholar
• Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;32A(14):2386-93
   PubMed Web of Science ®Google Scholar
• Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2(10):795-803
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;1023(5):1011-27
   PubMed Web of Science ®Google Scholar
• Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21(2):154-65
   PubMed Web of Science ®Google Scholar
• Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011;12(9):551-64
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;8358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2(10):727-39
   PubMed Web of Science ®Google Scholar
• Huang S, Robinson JB, Deguzman A, Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;160(19):5334-9
   PubMed Web of Science ®Google Scholar
• Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Teoh D, Secord AA. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int J Gynecol Cancer 2012;22(3):348-59
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;165(3):671-80
   PubMed Web of Science ®Google Scholar
• Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004;38(7-8):1258-64
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;7307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Burger RA, Sill MW, Monk BJ, Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;2025(33):5165-71
   PubMed Web of Science ®Google Scholar
• Cannistra SA, Matulonis UA, Penson RT, Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;2025(33):5180-6
   PubMed Web of Science ®Google Scholar
• Garcia AA, Hirte H, Fleming G, Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26(1):76-82
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Darcy KM, Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;129(16):2259-65
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, Burger RA, Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009;127(7):1069-74
   PubMed Web of Science ®Google Scholar
• Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96(3):902-5
   PubMed Web of Science ®Google Scholar
• McGonigle KF, Muntz HG, Vuky J, Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011;15117(16):3731-40
   PubMed Web of Science ®Google Scholar
• Del Carmen MG, Micha J, Small L, A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 2012;126(3):369-74
   PubMed Web of Science ®Google Scholar
• Belotti D, Vergani V, Drudis T, The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;Nov2(11):1843-9
   PubMed Web of Science ®Google Scholar
• Hurt JD, Richardson DL, Seamon LG, Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009;115(3):396-400
   PubMed Web of Science ®Google Scholar
• O'Malley DM, Richardson DL, Rheaume PS, Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011;1121(2):269-72
   PubMed Web of Science ®Google Scholar
• Gonzalez-Martin A, Gladieff L, Tholander B, Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): results from OCTAVIA. J Clin Oncol 2012;30(Suppl):abstract 5017
   Google Scholar
• Burger RA, Brady MF, Bookman MA, Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;29365(26):2473-83
   PubMed Web of Science ®Google Scholar
• Perren TJ, Swart AM, Pfisterer J, A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;29365(26):2484-96
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;1030(17):2039-45
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Nycum LR, Goff B, Gynecological cancers/ 967OUpdated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Ann Oncol 2012;23(Suppl 9):ix319
   Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl):abstract LBA5002
   Google Scholar
• Hagemann AR, Zighelboim I, Novetsky AP, Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30(Suppl):abstract 5013
   Google Scholar
• Tillmanns TD, Lowe MP, Walker MS, Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 2012; [Epub ahead of print]
   PubMedGoogle Scholar
• Miles D, Haas SD, Dirix L, Plasma biomarker analysis in the AVADO phase III randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer. Cancer Res 2010;70:24 Suppl 2: Abstract P2-16-04
   Google Scholar
• Van Cutsem E, de Haas S, Kang YK, Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;1030(17):2119-27
   PubMed Web of Science ®Google Scholar
• Lambrechts D, Claes B, Delmar P, VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13(7):724-33
   PubMed Web of Science ®Google Scholar
• Birrer MJ, Lankes H, Burger RA, Biomarkers/ 198 Biomarker results from GOG-0218, a phase III trial of front-line bevacizumab plus chemotherapy for ovarian cancer. Ann Oncol 2012;2012;23(Suppl 9):ix81-2
   Google Scholar
• Coleman RL, Duska LR, Ramirez PT, Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011;12(12):1109-17
   PubMed Web of Science ®Google Scholar
• Prescribing information of Avastin, Genentech, Inc. San Francisco, CA. 2012. Available from: http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf
   Google Scholar
• Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;2305(5):487-94
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Blank SV, Goff BA, An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer. J Clin Oncol 2012;30(Suppl):abstrACT 5054
   Google Scholar
• Cohn DE, Kim KH, Resnick KE, At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;129(10):1247-51
   PubMed Web of Science ®Google Scholar
• The Cancer Genome Atlas. National Cancer Institute at the National Institutes of Health. Bethesda, MD. Available from: http://cancergenome.nih.gov/
   Google Scholar
• Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;2101(23):1642-9
   PubMed Web of Science ®Google Scholar